Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361549 | 0.84 | ALDH1A1 (0.42) | ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL9073953 | 0.83 | TAS2R38 (0.37) | ALDH1A1POLB | |
| SCHEMBL30678963 | 0.82 | ALDH1A1 (0.41) | ALDH1A1POLB | |
| SCHEMBL968360 | 0.80 | CHRNB2 (0.43) | ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL7025880 | 0.80 | ALDH1A1 (0.40) | ALDH1A1POLB | |
| SCHEMBL22012853 | 0.80 | ALDH1A1 (0.40) | ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL10966308 | 0.80 | ALDH1A1 (0.40) | ALDH1A1POLB | |
| SCHEMBL11333124 | 0.78 | ALDH1A1 (0.51) | ALDH1A1POLBL3MBTL1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7021588 | 0.78 | ALDH1A1 (0.39) | ALDH1A1POLB | |
| SCHEMBL13719292 | 0.78 | ALDH1A1 (0.39) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4344702-A2 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2024-04-03 | — | — | EP | disclosed |
| EP-4076662-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-01-31 | — | — | EP | disclosed |
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | NOVARTIS AG (CH) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702409-B2 | Pyrazolyl derivatives useful as anti-cancer agents | PAK5, CYP51A1, SF3B5 | ALDH1A1 901/4885POLB 3028/4885L3MBTL1 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.